Effects of photobiomodulation therapy and pharmacological therapy at isolated and associated manner in experimental model of Duchenne Muscular Dystrophy

• Grant number: 15/21012-2
• Support Opportunities: Regular Research Grants
• Start date: March 01, 2018
• End date: February 29, 2020
• Field of knowledge: Interdisciplinary Subjects
• Principal Investigator: Lúcio Frigo
• Grantee: Lúcio Frigo
• Host Institution: Faculdade de Odontologia da Associação Paulista de Cirurgiões-Dentistas (FAOA/APCD-IESP). São Paulo , SP, Brazil
• Associated researchers: Ernesto Cesar Pinto Leal Junior

Abstract

Duchenne muscular dystrophy is a lethal disease caused by absence of dystrophin affecting one in every 3,500 males. The pre-clinical model widely used to study this disease is the mdx mice. These animals have complete absence of protein expression of dystrophin in their organism. Currently there isn't cure for DMD, however, the use of pharmacological therapy to control disease symptoms is widely used through glucocorticoids and NSAIDs, despite the often occurrence of adverse effects whit these treatments. With this aspects in mind, becomes very important the study of alternative therapies with high efficacy in decrease DMD symptoms, without undesirable effects. Photobiomodulation therapy (with lasers and LEDs) has been widely used to promote tissue regeneration, decreasing inflammation and pain relief, and it has been showing also positive results in delaying skeletal muscle fatigue in animals and humans, improving biochemical markers related to skeletal muscle recovery when this therapy is applied previously to exercise. Photobiomodulation therapy seems, therefore, to act as a protective therapy to muscular tissue. With these factors in mind, this project aims to analyze gene and protein expression of dystrophin, as well as analyze morphology and muscular function of mdx mice. For such, will be used different experimental groups that will be treated with photobiomodulation therapy and/or pharmacological therapy at isolated and associated manner for 14 weeks. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

TOMAZONI, SHAIANE SILVA; CASALECHI, HELIODORA LEAO; BACELAR FERREIRA, CHEILA DE SOUSA; SERRA, ANDREY JORGE; DELLE, HUMBERTO; DE OLIVEIRA BRITO, RODRIGO BARBOSA; DE MELO, BRUNNO LEMES; VANIN, ADRIANE AVER; RIBEIRO, NEIDE FIRMO; PEREIRA, AMANDA LIMA; et al. Can photobiomodulation therapy be an alternative to pharmacological therapies in decreasing the progression of skeletal muscle impairments ofmdxmice?. PLoS One, v. 15, n. 8, AUG 12 2020. (15/21012-2)

TOMAZONI, SHAIANE SILVA; CASALECHI, HELIODORA LEAO; BACELAR FERREIRA, CHEILA DE SOUSA; SERRA, ANDREY JORGE; DELLE, HUMBERTO; DE OLIVEIRA BRITO, RODRIGO BARBOSA; DE MELO, BRUNNO LEMES; VANIN, ADRIANE AVER; RIBEIRO, NEIDE FIRMO; PEREIRA, AMANDA LIMA; et al. Can photobiomodulation therapy be an alternative to pharmacological therapies in decreasing the progression of skeletal muscle impairments of mdx mice?. PLoS One, v. 15, n. 8, p. 16-pg., 2020-08-12. (15/21012-2)